kabutan

TSUMURA & CO.(4540) Summary

4540
TSE Prime
TSUMURA & CO.
3,840
JPY
-10
(-0.26%)
Dec 5, 11:30 am JST
24.76
USD
Dec 4, 9:30 pm EST
Result
PTS
outside of trading hours
3,842.1
Dec 5, 11:26 am JST
Summary Chart Historical News Financial Result
PER
11.7
PBR
0.97
Yield
3.75%
Margin Trading Ratio
6.74
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
3,837 JPY 24.73 USD
Previous Close Dec 4
3,850 JPY 24.77 USD
High Dec 5, 9:58 am
3,879 JPY 25.02 USD
Low Dec 5, 9:08 am
3,829 JPY 24.66 USD
Volume
68,200
Trading Value
0.26B JPY 1.69M USD
VWAP
3853.39 JPY 24.85 USD
Minimum Trading Value
384,000 JPY 2,476 USD
Market Cap
0.29T JPY 1.90B USD
Number of Trades
367
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
High
1-Year Average
1,429
1-Year High May 13, 2025
8,192
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 27,100 138,800 5.12
Nov 21, 2025 27,300 138,700 5.08
Nov 14, 2025 33,900 150,900 4.45
Nov 7, 2025 31,200 232,000 7.44
Oct 31, 2025 31,500 241,200 7.66
Company Profile
TSUMURA & CO. is the leading company specializing in Kampo medicines, expanding its focus on medications for the elderly, cancer patients, and women's health. The company is also developing its business in China.
Sector
Pharmaceuticals
TSUMURA & CO. primarily engages in the manufacture and sale of Kampo medicines, offering both prescription and over-the-counter pharmaceuticals. The company has established an integrated production system from the cultivation of raw medicinal herbs to product manufacturing, ensuring thorough quality control. In Japan, TSUMURA & CO. has secured its position as the undisputed top manufacturer of prescription Kampo preparations. In recent years, the company has been actively expanding into the Chinese market, strengthening its local production and sales capabilities through capital and business alliances with local enterprises. Furthermore, TSUMURA & CO. is advancing its global business operations, including drug development in the United States and cultivation of raw medicinal herbs in Laos. The company focuses on promoting Kampo medicine and developing evidence-based Kampo preparations to address the diversifying needs in healthcare.